The importance of CD8+ T-cell mediated CTL response in tumor protection was supported by in vivo antibody depletion experiments demonstrating depletion of CD8+ T cells abrogated the antitumor effect of anti-TIM-3/CD137 mAb. This evidence concerns the gene TNFRSF9 and neoplasm.